Neurogene Inc. (NGNE)Healthcare | Biotechnology | New York, United States | NasdaqGM
38.32 USD
-1.31
(-3.306%) ⇩
(July 13, 2026, 4 p.m.
EDT)
After hours: 37.56 -0.76 (-0.760%) ⇩ (July 13, 2026, 7:02 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 6:53 a.m. EDT
Neurogene presents a classic 'binary biotech' dilemma where the business thesis is compelling but the financial reality is precarious. The company has secured significant capital ($125M-$134M) to extend its runway into 2029, which is a crucial lifeline for a firm burning cash and reporting negative free cash flow. However, the balance sheet remains fragile with negative equity and a massive short interest (28%), signaling deep skepticism among traditional investors. The short-term outlook is cautiously optimistic due to the upcoming Phase 1/2 data readout for NGN-401. The options market is screaming for a catalyst, with heavy call buying at the $45 strike for late July, implying a belief that the data could trigger a massive re-rating similar to past rallies. Yet, the statistical forecast model is useless here, showing very low confidence, which aligns with the high volatility and lack of earnings visibility. Long-term, the investment case hinges entirely on the success of the Rett syndrome therapy. The stock has suffered a brutal multi-year decline (-85% over 9 years), reflecting the market's fear of failure in this high-risk sector. While the analyst consensus is a 'strong buy' with a target nearly doubling the current price, this is based on potential upside from a successful trial, not current profitability. For now, this is a speculative play on a specific clinical milestone, not a stable income or growth vehicle. |
| Model | MAE |
|---|---|
| MSTL_48 ✓ | 0.271428 |
| MSTL | 0.331573 |
| AutoARIMA | 0.344044 |
| AutoETS | 0.350097 |
| AutoTheta | 0.359314 |
| MSTL_48_90 | 0.398121 |
| MSTL_90 | 0.449691 |
Forecast horizon: 60 days | Selected: MSTL_48
| Forecast Reliability | |
|---|---|
| Score | 24% |
| H-stat | 4.00 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.008 |
| Excess Kurtosis | 0.98 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 3.84 |
| Market Cap | 764,496,000 |
| Forward P/E | -7.02 |
| Beta | 1.96 |
| Website | https://www.neurogene.com |
As of July 11, 2026, 6:53 a.m. EDT: Speculators are positioning for a binary event rather than a steady trend. Call volume is heavily skewed toward out-of-the-money strikes (45 strike) expiring in late July, suggesting a bet on a sharp spike driven by clinical data or regulatory news. Conversely, put volume is concentrated deep in-the-money (12.5 and 17.5 strikes) for January 2027, indicating a hedge against a prolonged failure or dilution scenario. The massive implied volatility spike on the far-dated deep puts versus zero IV on near-term deep calls confirms the market views the immediate future as volatile but potentially explosive, while the distant future carries a severe downside tail risk.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.7803235 |
| Address1 | 535 W 24th Street |
| Address2 | 5th Floor |
| All Time High | 1,115.0 |
| All Time Low | 6.875 |
| Ask | 48.37 |
| Ask Size | 2 |
| Audit Risk | 9 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 445,510 |
| Average Daily Volume3 Month | 210,888 |
| Average Volume | 210,888 |
| Average Volume10Days | 445,510 |
| Beta | 1.959 |
| Bid | 27.95 |
| Bid Size | 2 |
| Board Risk | 7 |
| Book Value | 15.227 |
| City | New York |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 38.32 |
| Current Ratio | 13.079 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 39.03 |
| Day Low | 37.26 |
| Debt To Equity | 3.84 |
| Display Name | Neurogene |
| Earnings Timestamp | 1,778,616,000 |
| Earnings Timestamp End | 1,786,478,400 |
| Earnings Timestamp Start | 1,786,478,400 |
| Ebitda | -107,454,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -3.457 |
| Enterprise Value | 371,476,832 |
| Eps Current Year | -5.31333 |
| Eps Forward | -5.4575 |
| Eps Trailing Twelve Months | -4.55 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 30.2318 |
| Fifty Day Average Change | 8.0882 |
| Fifty Day Average Change Percent | 0.26753947 |
| Fifty Two Week Change Percent | 78.03235 |
| Fifty Two Week High | 43.66 |
| Fifty Two Week High Change | -5.34 |
| Fifty Two Week High Change Percent | -0.12230875 |
| Fifty Two Week Low | 15.93 |
| Fifty Two Week Low Change | 22.39 |
| Fifty Two Week Low Change Percent | 1.4055241 |
| Fifty Two Week Range | 15.93 - 43.66 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,394,202,600,000 |
| Float Shares | 8,829,470 |
| Forward Eps | -5.4575 |
| Forward P E | -7.02153 |
| Free Cashflow | -47,845,624 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 131 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.0 |
| Gross Profits | -82,281,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.07072 |
| Held Percent Institutions | 0.88491 |
| Implied Shares Outstanding | 19,950,314 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,702,944,000 |
| Last Split Factor | 1:4 |
| Long Business Summary | Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company was founded in 2018 and is headquartered in New York, New York. |
| Long Name | Neurogene Inc. |
| Market | us_market |
| Market Cap | 764,496,000 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_602062523 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -98,638,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 788,835,415 |
| Number Of Analyst Opinions | 7 |
| Open | 38.76 |
| Operating Cashflow | -82,518,000 |
| Operating Margins | 0.0 |
| Overall Risk | 9 |
| Payout Ratio | 0.0 |
| Phone | 855 508 3568 |
| Post Market Change | -0.7599983 |
| Post Market Change Percent | -1.9832941 |
| Post Market Price | 37.56 |
| Post Market Time | 1,783,983,768 |
| Previous Close | 39.63 |
| Price Eps Current Year | -7.2120495 |
| Price Hint | 2 |
| Price To Book | 2.5165823 |
| Profit Margins | 0.0 |
| Quick Ratio | 12.903 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | -1.31 |
| Regular Market Change Percent | -3.30558 |
| Regular Market Day High | 39.03 |
| Regular Market Day Low | 37.26 |
| Regular Market Day Range | 37.26 - 39.03 |
| Regular Market Open | 38.76 |
| Regular Market Previous Close | 39.63 |
| Regular Market Price | 38.32 |
| Regular Market Time | 1,783,972,800 |
| Regular Market Volume | 235,775 |
| Return On Assets | -0.23909001 |
| Return On Equity | -0.37252 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 19,950,314 |
| Shares Percent Shares Out | 0.21180001 |
| Shares Short | 3,352,320 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 3,545,963 |
| Short Name | Neurogene Inc. |
| Short Percent Of Float | 0.2644 |
| Short Ratio | 16.62 |
| Source Interval | 15 |
| State | NY |
| Symbol | NGNE |
| Target High Price | 180.0 |
| Target Low Price | 46.0 |
| Target Mean Price | 81.71429 |
| Target Median Price | 69.0 |
| Total Cash | 243,182,000 |
| Total Cash Per Share | 15.389 |
| Total Debt | 9,130,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -4.55 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 24.22615 |
| Two Hundred Day Average Change | 14.093849 |
| Two Hundred Day Average Change Percent | 0.58176184 |
| Type Disp | Equity |
| Volume | 235,775 |
| Website | https://www.neurogene.com |
| Zip | 10,011 |